Prevention and control of hemorrhages in surface and internal capillaries of various etiologies, especially if the bleeding is caused by endothelial damage, in particular: prevention and treatment of bleeding during and after surgical operations in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery; prevention and treatment of capillary bleeding of various etiologies and localization: hematuria, metrorrhagia, primary hypermenorrhea, hypermenorrhea in women with intrauterine contraceptives, nasal bleeding, gum bleeding; neonatology prevention of periventricular bleeding in premature infants.
ETOL FORT №14 COMPOSITION
active substance: etodolac
1 tablet contains etodolac 400 mg
excipients: lactose, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, povidone,
Opadry II pink coating (85F240035): polyvinyl alcohol, titanium dioxide (E 171), iron oxide red (E172), polyethylene glycol 4000, talc.
ETOL FORT №14 DOSAGE FORM
MAIN PHYSICAL AND CHEMICAL PROPERTIES:
Non-steroidal anti-inflammatory and antirheumatic drugs. Acetic acid derivatives and related compounds. ATX code M01A B08.
ETOL FORT №14 PHARMACOLOGICAL PROPERTIES
Etodolac is an indolocic acid derivative NSAID, which differs from other non-steroidal anti-inflammatory drugs (NSAIDs) by the presence of the tetrahydropyranoindole core. Etodolac has anti-inflammatory, analgesic and antipyretic effects. The drug reduces the synthesis of prostaglandins (PG) from arachidonic acid, inhibiting the enzyme cyclooxygenase (COX), thereby reducing the sensitivity of receptors to pain mediators (histamine, bradykinin), reducing exudation, migration of leukocytes, as well as the sensitivity of hypothalamic centers of thermoregulation to the action of interleukin 1). Etodolac has moderate selectivity for COX-2, therefore it acts mainly in the focus of inflammation.
When taken orally, etodolac is rapidly absorbed in the digestive tract. The maximum concentration in blood plasma is reached after 1:00 and is 18 μg / ml. Plasma protein binding is 95%, the free fraction is 1.2-4.7%.
The plasma half-life is approximately 7:00. Etodolac is metabolized in the liver and excreted mainly by the kidneys (up to 60% in the form of metabolites). The volume of distribution is 0.4 l / kg, the clearance is 41 ml / h / kg. The bioavailability of etodolac is at least 80%. Ingestion of food and antacids does not affect bioavailability.
For urgent or long-term treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis.
Pain syndrome of various origins.
Hypersensitivity to the components of the drug a history of hypersensitivity reactions (for example, attacks of bronchial asthma, urticaria, rhinitis, angioedema) as a result of taking acetylsalicylic acid, ibuprofen or other NSAIDs active or recurrent ulcer / bleeding in history (two or more separate confirmed cases of ulcers or bleeding) gastrointestinal bleeding or perforation associated with previous NSAID therapy in the history of cytopenia, severe hepatic, renal, heart failure.
Contraindicated for the treatment of pain in coronary artery bypass grafting.